



Correction to: Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease

Katya Galactionova¹ · Paola Salari¹ · Renato Mattli² · Yael Rachamin^{3,4} · Rahel Meier^{3,4} · Matthias Schwenkglenks¹ 

Published online: 7 July 2022
© The Author(s) 2022

Correction to: PharmacoEconomics
<https://doi.org/10.1007/s40273-022-01152-8>

In the original online version, the first sentence of the Results section in the Abstract and the fourth sentence of the figure 2 legend have been incorrectly published.

The first sentence in the Results section previously read as:

Patients treated with inclisiran gained a 0.291 quality-adjusted life-year at an incremental cost per QALY gained of CHF 211,070/228,040 (life-long time horizon, discount rate 3%) under the lower/higher price.

It should read as:

Patients treated with inclisiran gained a 0.291 quality-adjusted life-year at an incremental cost per QALY gained of CHF 21,107/228,040 (life-long time horizon, discount rate 3%) under the lower/higher price.

The fourth sentence of the figure 2 legend previously read as:

The length of the bar indicates the resulting incremental cost-effectiveness ratio (ICER) when the respective parameter is set to its lower (lighter shade) and upper (darker shade)

bound values (see text for ranges); the diagram is centred on the base-case ICER, i.e. CHF 211,070/228,040 under the lower/higher inclisiran price assumption.

It should read:

The length of the bar indicates the resulting incremental cost-effectiveness ratio (ICER) when the respective parameter is set to its lower (lighter shade) and upper (darker shade) bound values (see text for ranges); the diagram is centred on the base-case ICER, i.e. CHF 21,107/228,040 under the lower/higher inclisiran price assumption.

The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s40273-022-01152-8>.

✉ Matthias Schwenkglenks
m.schwenkglenks@unibas.ch

¹ Institute of Pharmaceutical Medicine (ECPM), University of Basel, Basel, Switzerland

² Winterthur Institute of Health Economics, Zurich University of Applied Sciences, Winterthur, Switzerland

³ Institute of Primary Care, University of Zurich, Zurich, Switzerland

⁴ University Hospital Zurich, Zurich, Switzerland